Start-up Ra Pharma Emerges from Stealth, Targeting HAE
By Marie Powers
Thursday, May 17, 2012
Four years after its launch and two years after the company quietly secured a $27 million Series A round, Ra Pharmaceuticals Inc. revealed hereditary angioedema (HAE) as the initial target for its cyclomimetics peptide-like molecules that incorporate non-natural amino acids.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.